Skip to main content

Table 1 Baseline characteristics of the patients who reached the primary end-point (day 28)

From: Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial

   Quinine Atovaquone/Proguanil Artemether/Lumefantrine
n   30 30 30
sex m/f 16/14 16/14 18/12
age range 6 – 50 6 – 35 8 – 40
  mean 19.2 19.9 18.1
  median 16 18 17
Temperature (C°) range 36.0 – 39.5 36.0 – 39.3 35.6 – 39.9
  mean 37.4 37.3 37.5
  median 37.2 37.3 37.4
Parasitaemia range 360 – 63,000 400 – 69,880 480 – 83,600
  mean 15,469 13,028 21,189
  median 6,740 4,960 9,300
Symptoms Headache 30 30 30
  Nausea/vomiting 21 17 22
  Shivering 23 26 21
  Diarrhea 4 2 3
Actual daily dose (mg/kg) range 30.5 – 36 15 – 23 2.3 – 4.6
  mean 34.9 19.5 3.4
  stdev 1.6 1.9 0.6
  1. Baseline patients' characteristics of the patients who reached the primary end-point (day 28) were not significantly different between the three treatment groups in respect to age (Kruskal-Wallis-test, p = 0,504), sex (χ2-test, p = 0,835), parasitaemia (Kruskal-Wallis-test, p = 0,444), body temperature (Kruskal-Wallis-test, p = 0,860). There is also no significant difference in these baseline characteristics of the treatment groups when comparing all 97 treated patients.